Literature DB >> 8565308

T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis.

M E Griffith1, A Coulthart, C D Pusey.   

Abstract

T cell-mediated immune responses are likely to be important in the pathogenesis of systemic vasculitis. However, identifying the T cells involved has proved difficult, and there are conflicting reports regarding T cell proliferation in response to different autoantigens. Perinuclear (P) and cytoplasmic (C) anti-neutrophil cytoplasmic antibodies (ANCA) are closely associated with systemic vasculitis, and are generally specific for MPO or PR3, respectively. We studied the proliferative responses to MPO and PR3 of peripheral blood mononuclear cells from patients with P-ANCA or C-ANCA specific for these antigens by ELISA. These responses were compared with those of normal controls, and of disease controls with P- or C-ANCA not specific for MPO or PR3. The patient group as a whole showed significant T cell proliferation in response to the autoantigens compared with controls (P = 0.005). Cells from nine of 13 P-ANCA-positive, anti-MPO-positive patients proliferated in response to MPO, compared with five of 16 controls (P = 0.04). Cells from five of eight C-ANCA-positive, anti-PR3-positive patients proliferated in response to PR3, compared with two of 11 controls (P = 0.05). These experiments demonstrate that patients with P-ANCA or C-ANCA possess T cells which respond to MPO or PR3, respectively. As in other autoimmune diseases, responses to both antigens were also seen in a proportion of healthy controls. Further analysis of these responses will be important in understanding the pathogenesis of systemic vasculitis and in designing specific immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8565308      PMCID: PMC2200336          DOI: 10.1046/j.1365-2249.1996.d01-629.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

1.  Th2 dominance in nasal mucosa in patients with Wegener's granulomatosis.

Authors:  C E Balding; A J Howie; A B Drake-Lee; C O Savage
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

Review 2.  Cellular aspects of vasculitis--T cell-mediated aspects.

Authors:  M E Griffith; C D Pusey
Journal:  Springer Semin Immunopathol       Date:  2001

Review 3.  Off balance: T-cells in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides.

Authors:  P Lamprecht
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

4.  ANCA patients have T cells responsive to complementary PR-3 antigen.

Authors:  Jiajin Yang; David J Bautz; Sofia Lionaki; Susan L Hogan; Hyunsook Chin; Roland M Tisch; John L Schmitz; Barrak M Pressler; J Charles Jennette; Ronald J Falk; Gloria A Preston
Journal:  Kidney Int       Date:  2008-07-02       Impact factor: 10.612

5.  Analysis of T-cell receptor usage in myeloperoxidase--antineutrophil cytoplasmic antibody-associated renal vasculitis.

Authors:  Kouichi Hirayama; Takashi Ishizu; Homare Shimohata; Yasunori Miyamoto; Tomoko Kakita; Miho Nagai; Yujiro Ogawa; Shogo Fujita; Aki Hirayama; Kunihiro Yamagata; Masaki Kobayashi; Akio Koyama
Journal:  Clin Exp Nephrol       Date:  2009-10-07       Impact factor: 2.801

6.  Th17 cells promote autoimmune anti-myeloperoxidase glomerulonephritis.

Authors:  Poh-Yi Gan; Oliver M Steinmetz; Diana S Y Tan; Kim M O'Sullivan; Joshua D Ooi; Yoichiro Iwakura; A Richard Kitching; Stephen R Holdsworth
Journal:  J Am Soc Nephrol       Date:  2010-03-18       Impact factor: 10.121

Review 7.  Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.

Authors:  A J Barrett; K Rezvani
Journal:  Clin Exp Immunol       Date:  2007-05       Impact factor: 4.330

8.  Management of ANCA-associated vasculitis: Current trends and future prospects.

Authors:  Sally Hamour; Alan D Salama; Charles D Pusey
Journal:  Ther Clin Risk Manag       Date:  2010-06-24       Impact factor: 2.423

9.  T lymphocyte responses to anti-neutrophil cytoplasmic autoantibody (ANCA) antigens are present in patients with ANCA-associated systemic vasculitis and persist during disease remission.

Authors:  W J King; C J Brooks; R Holder; P Hughes; D Adu; C O Savage
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

10.  Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis?

Authors:  A-I Kälsch; M Soboletzki; W H Schmitt; F J van der Woude; A Hochhaus; B A Yard; R Birck
Journal:  Clin Exp Immunol       Date:  2008-01-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.